Inhibition of glycogen synthase kinase by curcumin: Investigation by simulated molecular docking and subsequent in vitro/in vivo evaluation

Journal of Enzyme Inhibition and Medicinal Chemistry
Yasser BustanjiHatim S Alkhatib

Abstract

Curcumin was investigated as an inhibitor of glycogen synthase kinase-3beta (GSK-3beta) in an attempt to explain some of its interesting multiple pharmacological effects, such as its anti-diabetic, anti-inflammatory, anti-cancer, anti-malarial and anti-alzheimer's properties. The investigation included simulated docking experiments to fit curcumin within the binding pocket of GSK-3beta followed by experimental in vitro and in vivo validations. Curcumin was found to optimally fit within the binding pocket of GSK-3beta via several attractive interactions with key amino acids. Experimentally, curcumin was found to potently inhibit GSK-3beta (IC50 = 66.3 nM). Furthermore, our in vivo experiments illustrated that curcumin significantly increases liver glycogen in fasting Balb/c mice. Our findings strongly suggest that the diverse pharmacological activities of curcumin are at least partially mediated by inhibition of GSK-3beta.

References

Aug 1, 1976·Biochemical Pharmacology·O P Sharma
Jun 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·T S HuangJ K Lin
Oct 20, 1995·The Journal of Biological Chemistry·S Singh, B B Aggarwal
Oct 20, 1998·Wound Repair and Regeneration : Official Publication of the Wound Healing Society [and] the European Tissue Repair Society·G S SidhuR K Maheshwari
Dec 10, 1999·Journal of Agricultural and Food Chemistry·P S NegiK K Sakariah
Aug 13, 2002·Current Topics in Medicinal Chemistry·William H BullockJoachim Rudolph
Jul 23, 2003·The Journal of Biological Chemistry·Francesca DemarchiClaudio Schneider
Aug 21, 2003·The Journal of Biological Chemistry·Ratan BhatJesús Avila
Dec 30, 2003·Journal of Medicinal Chemistry·Guy P A Vigers, James P Rizzi
Jan 23, 2004·Journal of Medicinal Chemistry·Maria KontoyianniGlenn S Sokol
Mar 23, 2004·Current Medicinal Chemistry·M Alonso, A Martinez
Apr 24, 2004·Science·Marie E EganMichael J Caplan
Dec 14, 2004·The Journal of Biological Chemistry·Fusheng YangGregory M Cole
Aug 6, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R A SharmaW P Steward
Jan 18, 2006·Life Sciences·Radha K MaheshwariRikhab C Srimal
Sep 28, 2006·Clinical and Experimental Pharmacology & Physiology·Sameer SharmaKanwaljit Chopra
Feb 24, 2007·Journal of Natural Products·Florastina PaytonWilliam L Alworth
Jun 16, 2007·Advances in Experimental Medicine and Biology·Girija KuttanRamadasan Kuttan
Jun 16, 2007·Advances in Experimental Medicine and Biology·Chih-Hung Hsu, Ann-Lii Cheng
Jan 16, 2008·Bioorganic & Medicinal Chemistry·Satyendra MishraAvadhesha Surolia
Feb 26, 2008·European Journal of Pharmacology·Mohammad K MohammadYasser Bustanji
May 17, 2006·Journal of Agricultural and Food Chemistry·Krishnan Balasubramanian

❮ Previous
Next ❯

Citations

Oct 8, 2011·Natural Product Reports·Subash C GuptaBharat B Aggarwal
Jun 2, 2011·International Journal of Alzheimer's Disease·Jari KoistinahoGundars Goldsteins
Dec 24, 2015·Journal of Medicinal Chemistry·Rita M C Di MartinoFederica Belluti
Jun 16, 2009·Trends in Pharmacological Sciences·Xiu-Zhen ZhangHong-Yu Zhang
Dec 27, 2008·Trends in Pharmacological Sciences·Bharat B Aggarwal, Bokyung Sung
Apr 18, 2015·Phytotherapy Research : PTR·O O AdewaleT Tencomnao
Apr 20, 2012·Journal of Enzyme Inhibition and Medicinal Chemistry·Mohammad MohammadYasser Bustanji
Oct 30, 2010·Journal of Enzyme Inhibition and Medicinal Chemistry·Yasser BustanjiHatim S Alkhatib
Aug 31, 2014·Drug Discovery Today·Andreas Koeberle, Oliver Werz
Jan 14, 2011·Bioscience, Biotechnology, and Biochemistry·Jun YoshidaKen-ichi Kimura
Aug 7, 2016·Nutrition & Metabolism·Xunxian Liu, Zemin Yao
Jan 12, 2017·Journal of Medicinal Chemistry·Kathryn M NelsonMichael A Walters
Feb 2, 2017·Journal of Medicinal Food·Amatul Hamizah AliHasidah Mohd Sidek
Jun 22, 2016·BioFactors·Angélica Saraí Jiménez-OsorioSilvestre Alavez
Sep 1, 2017·Acta Pharmaceutica : a Quarterly Journal of Croatian Pharmaceutical Society and Slovenian Pharmaceutical Society, Dealing with All Branches of Pharmacy and Allied Sciences·Mahmood AhmedAbdullah M Asiri
Jan 28, 2014·Interdisciplinary Sciences, Computational Life Sciences·Arpitha Badarinath MahajanakattiSinosh Skariyachan
Jan 14, 2017·Fish Physiology and Biochemistry·Pollyanna de Moraes França FerreiraJener Alexandre Sampaio Zuanon
Sep 7, 2018·Frontiers in Pharmacology·Aminu Mohammed, Md Shahidul Islam
Jul 11, 2018·Proceedings of the National Academy of Sciences of the United States of America·Sourav BanerjeeXing Guo
Aug 28, 2020·Neurotoxicity Research·Pranglada JearjaroenJiraporn Tocharus
Apr 10, 2020·Current Pharmaceutical Design·Tarique HussainDildar H Kalhoro
Feb 9, 2021·Journal of Diabetes and Metabolic Disorders·Vishakha Parab Gaonkar, Kirankumar Hullatti
Jul 31, 2013·Journal of Agricultural and Food Chemistry·Jun YoshidaKen-Ichi Kimura
Aug 28, 2021·Antioxidants·Maria Assunta PotenzaMonica Montagnani

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.